Underuse of Parkinson's device questioned in Germany
This article was originally published in Clinica
Germany lags behind the majority of western European countries in providing patients suffering from Parkinson's disease with pioneering therapy in the form of a deep brain stimulation device (see Clinica No 1002, p 23), claims the European Parkinson's Disease Association (EPDA). Medtronic's Activa Parkinson's Control Therapy device could be used to treat an estimated 20% of sufferers, it says, but it is used on only 5.2% of patients in Germany.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.